

Abdominal massage for the alleviation of constipation symptoms in people with multiple sclerosis: a randomized controlled feasibility study

Doreen McClurg¹, Suzanne Hagen¹, Stanley Hawkins² and Andrea Lowe-Strong³

Abstract

Background: Constipation affects many people with multiple sclerosis (MS), negatively impacting on their quality of life. The use of abdominal massage has been reported in several populations and has been shown to increase the frequency of defaecation.

Objective: The objective of this study was to determine the feasibility of undertaking abdominal massage in people with MS.

Methods: Following ethical approval, 30 patients with MS and constipation were recruited. After providing informed written consent and completion of baseline outcome measures, participants were randomly allocated to a massage group or a control group. The massage group participants were provided with advice on bowel management, and they or their carers were taught how to deliver abdominal massage and were recommended to perform it daily during the 4-week intervention period. The control group received bowel management advice only. Outcomes were measured pre (Week 0) and post treatment (Week 4), and at Week 8 and included: the Constipation Scoring System (CSS) (primary outcome), the Neurogenic Bowel Dysfunction Score, and a bowel diary.

Results: Both groups demonstrated a decrease in CSS score from Week 0 to Week 4, indicating an improvement in constipation symptoms; however, the massage group improved significantly more than the control groups (mean difference between groups in score change -5.0 (SD 1.5), 95% CI $-8.1, -1.8$; $t = -3.28$, $df = 28$, $p = 0.003$).

Conclusion: The results of this small study suggest a positive effect of the intervention on the symptoms of constipation, and support the feasibility of a substantive trial of abdominal massage for the alleviation of the symptoms of constipation in people with MS.

Keywords

quality of life, symptomatic treatment

Date received: 3rd May 2010; revised: 1st August 2010; accepted: 24th August 2010

Introduction

Bowel dysfunction occurs in 45–69% of people with multiple sclerosis (MS).¹ However, despite the high prevalence, a Cochrane Review on the ‘Management of faecal incontinence and constipation in adults with central neurological diseases’ reported there was remarkably little research in this area, and concluded that ‘no recommendations could be drawn for bowel management which must remain empirical’.² Constipation is an unpleasant and often distressing condition, and within the MS population can affect patients at anytime during the disease process.³ Although rarely life threatening, the distress associated with constipation can affect the overall well-being of a patient, with symptom severity correlating negatively

with perceived quality of life.⁴ It has also been shown that constipation is a source of considerable psychosocial disability and can influence patients’ daily lives to such an extent that they can become totally preoccupied with the symptoms.^{1,5–7} Such symptoms can range

¹Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, UK.

²Neurology Department, Queens University, Belfast, UK.

³Health and Rehabilitation Sciences Research, Institute and School of Health Sciences, School of Health, University of Ulster, UK.

Corresponding author:

Doreen McClurg, Nursing, Midwifery and Allied Health Professions Research Unit, Buchanan House, Cowcaddens Road, Glasgow Caledonian University, Glasgow, G4 0BA, UK
Email: Doreen.mcclurg@gcal.ac.uk

from a headache and fatigue to feelings of bloatedness, loss of appetite, nausea, vomiting, overflow incontinence and, concomitantly in the MS patient, exacerbated limb spasticity and bladder dysfunction.

Constipation in people with MS has multiple causes and cannot be linked to a single identifiable neurological deficit.⁸ Three broad types of constipation have been identified.

Defaecatory disorders

Pelvic floor muscles may be altered leading to pelvic floor dyssynergia, where the external anal sphincter tightens rather than opens during defaecation, which leads to straining and incomplete bowel evacuation.⁹

Transit disorders

Abnormalities of colonic activity and a slow transit time have been shown to cause constipation in those with MS.^{10–12} In a study of six patients with MS, transit studies revealed that five had abnormally slow transit, with delay being primarily in the distal colon.¹³ It has also been speculated that slow transit might be due to an autonomic nervous system deficit such as occurs with a central nervous lesion rostral to the thoracic cord.¹⁰ However, constipation can also occur in patients with little general neurological disability due to MS. An alternative speculative hypothesis is that slow transit is not due to a specific neurological lesion or lesions in the central nervous system, but rather to another mechanism similar to that which causes fatigue in the disease, which is not understood.⁸

Other predisposing factors

Constipation may be related to factors such as fibre and fluid intake, mobility, general weakness and fatigue. Medications commonly prescribed to patients with MS, such as muscle relaxants or anticholinergic drugs, are also known to cause constipation.¹⁴ Finally, psychological factors or behavioural problems may also affect toileting. The end result of such influences is a reduced peristalsis, which may exacerbate a slow bowel transit time, resulting in faecal matter that is harder and dryer than normal, causing difficult and often painful defaecation.¹⁴

Abdominal massage for the management of constipation was used as early as 1870, with its use reaching a peak in the late 19th and early 20th century, yet by the 1950s the therapies had all but disappeared. However, massage has undergone a revival in clinical practice, especially within the palliative care, oncology and hospice environments.^{15,16} Indeed, the MS Trust and the MS Society both advocate its use for the relief of

constipation,^{17,18} but there is very little research as to its effectiveness. A literature review undertaken in 1999 by Ernst¹⁹ concluded that this intervention should be further investigated through more robust trials. Since 1999 several studies have been undertaken, the most recent of which recruited a sample of 60 people with constipation who were randomized to two groups: an intervention group which received the massage, and a control group.²² These authors concluded that the abdominal massage decreased the severity of constipation and increased bowel movements but did not lead to decrease in laxative intake. The present paper describes a pilot study on the efficacy of abdominal massage for the relief of constipation in people with MS.

Methods

Ethical approval for the study was obtained from the Office for Research Ethics Committees, Northern Ireland (ORECNI: 08/NIRO2/80: 25th September 2008).

Participants and recruitment

Following consultation with a statistician it was recommended that we recruit 30 participants in order to adequately test out the trial procedures and provide a robust estimate of the intervention effect size to inform sample size calculations for a definitive randomized controlled trial.

Participants were recruited over a 6-month period and self-referred in response to adverts placed in the Northern Ireland MS Magazine and website, and through the principal investigator visiting various MS Groups and day centres to discuss the proposed study.

The project was explained fully to all participants, and an information sheet was provided. The initial screening of individuals included a medical history and a pre-trial questionnaire which recorded the participant's age, time since diagnosis, disease course and Expanded Disability Status Scale (EDSS). Included were individuals who were over 18 years of age, had a confirmed diagnosis of MS, fulfilled the Rome II criteria for constipation (Figure 1) and were able to understand and agree to the study protocol. Excluded were those with a medical history of Crohn's disease, diverticular disease, colon cancer, rectal bleeding or recent change in bowel function (Figure 2).

Group allocation

Written informed consent was obtained from each participant, and following completion of baseline outcome measures participants were randomly allocated by the therapist using a web-based

To make a diagnosis of constipation the patient must report two or more of the following:

- a. Straining during at least 25% of defecations
- b. Lumpy or hard stools in at least 25% of defecations (Bristol Stool Chart 1 or 2)
- c. Sensation of incomplete evacuation for at least 25% of defecations
- d. Sensation of anorectal obstruction/blockage for at least 25% of defecations
- e. Manual manoeuvres to facilitate at least 25% of defecations (e.g. digital evacuation, support of the pelvic floor)
- f. Fewer than three defecations per week

Loose stools are rarely present without the use of laxatives

Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Figure 1. Rome II Criteria for Constipation.

(Douglas A. Drossman. ROME II: The Functional Gastrointestinal Disorders, Second Edition).

system, (<http://www.sealedenvelop.com>), to Group 1 (massage group) or Group 2 (control group). The individual was informed by telephone and an appointment made for the first visit by the therapist.

Intervention

The intervention period was 4 weeks, with participants in both groups receiving weekly visits from the physiotherapist, thus controlling for the potential effects of contact with a clinician. During these visits discussions on the patient's bowel patterns and symptoms were initiated by the physiotherapist and advice was given as necessary regarding good defaecation posture, adequate fluid intake, and the importance of diet and exercise.

In addition, Group 1 participants were instructed, at the first and subsequent visits if necessary, how to carry out abdominal massage by the therapist. The participant was positioned supine with head and shoulders supported and initially the abdomen was assessed for flatus, pain and faecal matter in the gut. The massage began with a gentle relaxing stroke up the abdominal wall. Four basic strokes were then provided – stroking, effleurage, kneading and vibration (see Figure 3). During the visits the patient and carer were instructed in the technique and were given the opportunity to practice and ask questions. A teaching DVD which demonstrated the techniques was also provided. The abdominal massage protocol lasted approximately

15 min and it was advised that it should be carried out daily by the participant or their carer.

Outcome measurement (OCM)

Outcome data were gathered at baseline (Week 0), at the end of the intervention phase (Week 4) and 4 weeks later (Week 8). The questionnaires were administered to participants via telephone by an outcome assessor blinded to group allocation. Participants were also asked to complete a daily bowel diary during the 7 days prior to baseline, during the 4 weeks of intervention, and for 7 days prior to the completion of the Week 8 questionnaire.

Primary outcome measure

Constipation Scoring System. The Constipation Scoring System (CSS)²³ is an 8-item questionnaire with items on frequency of bowel movement, difficulty with evacuation, feeling of incomplete evacuation, pain, length of time for evacuation, assistance with evacuation (e.g. laxatives), number of failed attempts and the duration of problems with constipation. The maximum score is 30, with a higher score indicating increased severity. The CSS was chosen as the primary outcome measure as there is no validated OCM specific to patients with MS and constipation, and this was deemed to be most appropriate for use in this group of patients at the time.




Figure 2. Recruitment and progress of participants through study.

Stroking commenced from the small of the back and followed the dermatome of the vagus nerve, over the iliac crests, and down both sides of the pelvis towards the groin. This was repeated several times.

Effleurage strokes followed the direction of the ascending colon across the transverse colon and down the descending colon. This was repeated several times with increased pressure to stimulate the austral and segmental contractions of the large intestine with the aim of propelling the faecal matter along the gut.

Palmar kneading is the heart of the massage and tracks down the descending colon, up the ascending colon, and down the descending colon once again. Kneading assists in propelling the faecal matter along the gut to load the rectum. Finger kneading may be required to break up faecal mass. This part of the massage may sometimes be uncomfortable because of the deep compression required.

Effleurage was repeated and continued with a relaxing transverse stroke over the abdomen.

Vibration over the abdominal wall to relieve flatus concluded the massage session.

Figure 3. Massage technique.

Secondary outcome measures

Neurogenic Bowel Dysfunction Score. The Neurogenic Bowel Dysfunction Score (NBDS)²⁴ is a 10-item questionnaire covering frequency of bowel movements (0–6 points), headache, perspiration or discomfort before or during defaecation (0–2 points), medication (0–4 points each), time spent defaecating (0–7 points), frequency of digital stimulation or evacuation (0–6 points), frequency of faecal incontinence (0–13 points), medication to prevent faecal incontinence (0–4 points), flatus incontinence (0–2 points) and perianal skin problems (0–3 points). The maximum score in the NBDS is 47; the higher the score the more severe the symptoms, with a score of 14 or more rated as severe. The NBDS is a validated outcome measure for bowel dysfunction in patients with spinal cord injuries and was selected for use in this study as a possible OCM in people with MS.

Multiple Sclerosis Impact Scale. The Multiple Sclerosis Impact Scale (MSIS-29)²⁵ scale was designed to measure the physical and psychological impact of MS. It is a 29-item questionnaire with two subscores measuring Physical (20 items) and Psychological (9 items) impact, with higher scores indicating greater impact.

The MSIS was selected as a generic measure of the quality of life of patients with MS and would monitor changes in the physical or psychological condition of the participants.

The Qualiveen Questionnaire. The Qualiveen Questionnaire²⁶ is a 30-item questionnaire assessing bladder-related quality of life in neurological patients. Four subscales representing aspects of patients' lives (bother with limitations, frequency of limitations, fears and feelings) are assessed with response options framed as 5-point scales, with 0 indicating no effect and 4 indicating a high adverse effect. Results can be presented by subscale and total score. The Qualiveen was used as an OCM as it is a validated measure of bladder symptoms in people with MS, and we wanted to monitor any changes in bladder symptoms in our participants. Constipation is thought to affect bladder function and it was therefore important to record such changes.

7-day bowel diary. This diary recorded for each of seven consecutive days:

- Number of times the participant defaecated each day
- How long the person spent trying to defaecate
- Type of bowel motion (Bristol Stool Chart)
- Number of episodes of faecal incontinence
- Feeling of incomplete evacuation

- Use of laxatives/enemas
- Change in medication, diet and fluid intake

Analysis

Data were entered into a study database by a member of the team who was blinded to participants' group allocation. Analysis was undertaken using SPSS Version 17 with group allocation concealed using codes to differentiate between the massage and control arms. Comparison of the baseline characteristics of the two study groups was undertaken using the independent sample *t*-test or the chi square test. Changes in scores from pre to post intervention (from Week 0 to Week 4 and Week 8) were compared between study groups using the independent sample *t*-test. The distribution of study variables was assessed for normality to ensure the use of parametric tests was appropriate. A 5% level of significance was used throughout.

Results

Baseline characteristics

Of the first 41 people who expressed an interest in the study 30 individuals (12 male and 18 female) fulfilled the inclusion criteria and were recruited and randomized between March and October 2009 (Figure 2). The mean age of the group was 55 years (SD 13; median 56; range 34–83 years) and mobility (EDSS 2.5–6.0) varied from walking unaided (10%) to wheelchair bound (40%) (Table 1).

Although there was no statistically significant difference between the demographic characteristics at baseline, Group 2 had seven patients with an indwelling catheter which appears to be a high number as the mean EDSS was 3.5. However, all the patients with an EDSS score of 6 had indwelling catheters within this group. There was no statistically significant difference demonstrated between the groups in any outcome measures at baseline.

Recruitment, retention and compliance

All participants remained in the study up to the end of the intervention period (Week 4); one participant, from the control group, withdrew due to a relapse before the final outcome measures were completed at Week 8 (Figure 2).

In terms of compliance with the abdominal massage, all participants in Group 1 received a weekly visit during the intervention period and reported undertaking the massage daily. At Week 8 it was reported by

Table 1. Demographic characteristics

	Group 1 Treatment	Group 2 Control	p value (Independent sample t-test, Chi square test)
Gender	5 male, 10 female	7 male, 8 female	0.36
Age range (years), mean (years)	(33–77) 52.4	(34–83) 59.3	0.16
SD	12.32	14.7	
Type of MS	8	10	0.19
Secondary progressive	6	1	
Relapsing–remitting	1	3	
Primary progressive	0	1	
Benign			
EDSS: mean (SD) Range	2 (1)1–5	3 (1)1–6	0.42
Bladder Problem	14	13	
Intermittent self-catheterization	7	3	0.13
Indwelling catheter	2	7	0.10
Laxative use			
No laxatives	6	6	
Movicol	4	8	
Lactulose	3	1	
Other	2	0	

80% of participants that they were continuing with the massage.

Data from the bowel diary could only be analysed at baseline and Week 4 as the diaries were poorly completed at Week 8.

Primary outcome measure

Constipation Scoring System. Both groups' CSS scores decreased from Week 0 to Week 4 (Table 2, Figure 4), indicating an improvement in constipation symptoms; however, the massage group improved significantly more than the control group (mean difference between groups in score change -5.0 (SD 1.5), 95% CI $-8.1, -1.8$; $t = -3.28$, $df = 28$, $p = 0.003$). There was no difference between groups in CSS score improvement between Week 0 and Week 8 (mean difference between groups in score change -1.6 (SD 1.5), 95% CI $-5.6, 0.6$; $t = -2.64$, $df = 28$, $p = 0.112$) (Table 3).

Secondary outcome measures

Neurogenic Bowel Dysfunction Score. The NBDS decreased (improved) in the massage group but increased (worsened) in the control group (Table 2, Figure 5), the difference between groups being statistically significant from Week 0 to Week 8 (mean

difference between groups in score change -7.35 (SD 2.4), 95% CI $-12.45, -2.25$; $t = -2.95$, $df = 27$, $p = 0.006$), but not for Week 0 to Week 4 (mean difference between groups in score change -4.4 (SD 2.5), 95% CI $-9.6, 0.68$; $t = -1.77$, $df = 28$, $p = 0.086$) (Table 4).

Bowel diary (baseline and Week 4 data only). The frequency of defaecation increased (improved) in both groups but the participants in the massage group improved more than the control group (Figure 6), the difference between groups being statistically significant for the change from Week 0 to Week 4 (mean difference between groups in score change -2.2 (SD 0.58), 95% CI $-0.98, -0.97$; $t = 3.7$, $df = 27$, $p = 0.001$).

There was no change reported by participants in laxative use in Group 2, and one person in Group 1 reduced their laxative intake at Week 4 compared with baseline. In response to the question on stool consistency, more participants in both groups scored a 3 or 4 (indicating softer stools) on the Bristol Stool Chart Scale at Week 4, while at baseline most patients in both groups scored a 1 or 2 (indicating constipation). In the intervention group the mean time spent defaecating was reduced from 10 min at baseline to 6 min at Week 4 (per day), and in the control group the time was reduced from 12 min to 10 min per day.

Table 2. Raw data of the Constipation Scoring System and the Neurogenic Bowel Dysfunction Score

Time point	Gp	Constipation Scoring System			Neurogenic Bowel Dysfunction Score		
		Mean/SD	95% CI of the Difference (Paired Samples t-test)	Sig	Mean/SD	95% CI of the Difference (Paired Samples t-test)	Sig
Baseline	1	13.20 +/- 3.745			11.87 +/- 5.998		
Week 4	1	7.533 +/- 3.31375	Lower 3.15786 Upper 8.17547	.000	7.60 +/- 5.17963	Lower 1.06593 Upper 8.59926	0.053
Week 8	1	9.600 +/- 3.35517	Lower 1.36714 Upper 5.83286	.004	6.86 +/- 3.7712	Lower 1.56706 Upper 8.43294	0.007
Baseline	2	10.73 +/- 4.891			8.27 +/- 7.186		
Week 4	2	10.06 +/- 3.453	Lower -1.42294 Upper -2.75627	.505	8.46 +/- 8.6178	Lower -3.41002 Upper 3.01002	0.896
Week 8	2	10.14 +/- 3.6973	Lower -1.38305 Upper -3.52591	.363	11.07 +/- 7.0159	Lower -6.50595 Upper 1.79166	0.241

Group 1 Treatment Group, Group 2 Control Group.

Table showing Mean and SD at Baseline, Week 4 and Week 8 and change in score within each group from baseline for the Constipation Scoring System and the Neurogenic Bowel Dysfunction Score.




Figure 4. Line graph showing change in Constipation Scoring System.

Multiple Sclerosis Impact Scale. There was no significant change in the score of the Physical or Psychological subgroups at any time point.


Qualiveen questionnaire. There was no significant difference between groups in the Total Qualiveen scores at any time point (mean difference between groups in score change (Week 0 to Week 4) -0.11 (SD 0.16), 95% CI $-0.45, 0.23$; $t = -0.673$, $df = 27$, $p = 0.506$; (Week 0 to Week 8) 0.29 (SD 0.25), CI $-0.23, 0.81$; $t = 1.169$, $df = 25$, $p = 0.253$). According to Bonniaud et al.,²⁷ the minimal important difference in score to interpret the magnitude of treatment effect is 0.5 in any of the four domains. There was an average change of 0.68 from baseline to Week 4 in the massage group in the ‘bother’ domain, and similarly an average change of 0.63 from baseline to Week 8 in this domain in the control group.

Discussion

This is the first study which has exclusively involved patients with MS undertaking a programme involving abdominal massage for the relief of constipation. From the findings it would appear that using abdominal massage improves the frequency of defaecation. Furthermore, retention in the massage group was 100% and there were no adverse incidents reports, indicating that it is a feasible intervention for people with

Table 3. Change in Constipation Scoring System

Change	Group	n	Mean difference	SD	Independent sample t-test p value
Baseline–Week 4	Gp 1 Intervention	15	–5.6667	4.5	0.003
	Gp 2 Control	15	–.6667	3.7	
Baseline–Week 8	Gp 1 Intervention	15	–3.6000	4.0	0.112
	Gp2 Control	14	–1.0714	4.25	

**Figure 5.** Line graph showing change in Neurogenic Bowel Dysfunction Score.

MS to undertake and that it is amenable to being evaluated within a randomized controlled trial design.


The causes of constipation are multi-factorial, and abdominal massage should be used as part of an integrated bowel management programme. Both groups received the same advice on good defaecation posture, fluid intake, diet and exercise, and an improvement in the CSS was evident in all participants. However, those that received the abdominal massage improved significantly more on the CSS than those that received the advice only ($p = 0.003$, 95% CI $-8.1, -1.8$; $t = -3.28$, $df = 28$) and in the frequency of defaecation ($p = 0.001$, 95% CI $-0.98, -0.97$; $t = 3.7$, $df = 27$). Anecdotally, participants also found the abdominal massage relaxing, and it was interesting that the majority of participants were keen to undertake the massage themselves as it provided a means of self-help and empowerment.

There is debate as to the mechanisms of action of abdominal massage on the bowel, with several possible explanations. It is thought that rectal loading may be encouraged by increasing intra-abdominal pressure, and in some neurological cases it may elicit rectal waves which stimulate the somato-autonomic reflex and bowel sensation.²⁸ The mechanical and reflex effect on the gut encourages peristalsis, enhancing the mass movement of the gut and so increasing the strength of the contraction and propulsive force. The function of the gastrointestinal tract is also influenced by activity in the parasympathetic division of the autonomic nervous system. By sensory stimulation of the parasympathetic division there is increased mobility of the muscles of the gut, an increase in the digestive secretions and relaxation of the sphincters in the gastrointestinal canal.^{29,30} In one study of preterm neonates, massage influenced weight gain by increasing vagal activity and gastric motility.³¹

The findings of the current study support work in other patient populations. The most recent of these was a two-group randomized study of 60 self-referred patients, who fulfilled the Rome 11 criteria for constipation; the massage group ($n = 30$) received 8 weeks of abdominal massage administered by a clinician, and the control group ($n = 30$) received no additional intervention or contact time. Results demonstrated an increase in frequency of defaecation in the massage group, but no change in laxative use.²² In 2005, a two-group randomized controlled trial comparing abdominal massage ($n = 16$) with no massage ($n = 15$) in patients who had suffered a cerebrovascular accident reported significant advantage for the treatment group in terms of increased frequency of defaecation and reduced severity of constipation.²¹ Preece²⁰ reported some relief of symptoms in the palliative care setting. Patients were taught the technique at the day-care centre and used it at home. However, the study sample size ($n = 15$) was small and there was no control group. Anecdotal evidence and expert opinion also suggests abdominal massage to be an effective treatment option for the management of constipation, with the added advantage that it is perceived by patients to be relaxing and provides relief from 'trapped wind'.^{32–34} Yet rigorous evidence of the

Table 4. Change in Neurogenic Bowel Score

Change	Group	<i>n</i>	Mean difference	SD	Independent sample <i>t</i> -test <i>p</i> value
Baseline–Week 4	Gp 1 Intervention	15	−4.2667	7.8	0.086
	Gp 2 Control	15	0.2000	5.8	
Baseline–Week 8	Gp 1 Intervention	15	−5.0000	6.1	0.006
	Gp 2 Control	14	2.35711	7.2	

**Figure 6.** Frequency of defaecation.

effectiveness and cost-effectiveness of abdominal massage for the management of constipation is still lacking, despite The Royal College of Physicians suggesting some years ago that randomized controlled trials were needed to address this evidence gap.³⁵ The results of the current study add to the available evidence and, following the Medical Research Council guidance³⁶ on developing and evaluating complex interventions, equip us with the information needed to undertake a multi-centre randomized controlled trial adequately powered to detect differences across a range of outcomes which are important to patients with MS.

It was interesting that many of the participants found the bowel diary a useful tool both for monitoring frequency of defaecation and as an aid to remember to take their laxative medication. Some also said it was useful as the Bristol Stool Chart gave them the language to use when discussing their constipation with

clinicians. Most participants also found the DVD demonstrating the massage was very useful, although one participant with partial sight had difficulty seeing it.

All outcome measures, except for the bowel diary, were completed by telephone administration. This was felt an appropriate method for this particular group of patients because of the potential problems with eyesight and although it could be time consuming for the research assistant it facilitated 100% completion.

The results of the NBDS are interesting in that they indicated a slight worsening of the overall symptoms relating to bowel dysfunction within the control group. Although the total score of frequency of defaecation decreased, indicating a slight improvement, the scores for two of the questions – the use of digital stimulation and the frequency of faecal incontinence – both increased in this group. At baseline no patients admitted to using digital stimulation, at Week 4 one participant was using it and at Week 8, two patients were using it, increasing the score from 0 to 6 and 12, respectively. In the frequency of faecal incontinence at 8 weeks two patients stated they had daily faecal incontinence episodes (scoring 13) as opposed to between 1–6 days (scoring 6 points). Also from the results of the NBDS the intervention group continued to improve from Week 4 to Week 8, whereas in the CSS they did not. It would appear that this was due to a decrease in faecal incontinence, although those who continued to use the massage may also have a further beneficial effect.

There are several limitations to this study. Results should be interpreted with caution due to the small sample size, which reflects the feasibility nature of the study. Outcome measures such as the NBDS may also not be sensitive enough to detect accurate changes within either an MS population or in such small numbers, but again testing outcome measures was another aim of the study. Patients self-referred to the study and were therefore potentially more motivated than the general MS population, and due to the nature of the intervention it was not possible to blind the patient or clinician. Abdominal massage also requires a period of time to influence constipation. In the present study the duration of the massage (4 weeks) was quite short

compared with other studies; for example Lamas et al.²² only found significant differences at Week 8, and it may be the effect would have continued to increase if the duration of intervention had been longer. Furthermore, some participants felt that in applying the massage technique themselves they were unable to exert the same pressure achieved by the physiotherapist, and also it could be quite fatiguing. This could reduce the potential effect of the intervention.²² This was, however, a pragmatic pilot study whereby we were testing the feasibility of either a carer or the patient themselves undertaking the massage. Although all participants received the same training with weekly visits which usually incorporated a massage session, standardization of the abdominal massage technique, especially if undertaken by the participants, was difficult.

Although the results of this trial cannot definitively recommend the use of abdominal massage, it would appear that with adequate training provided to the clinician, patient or carer it is has potential in a programme of treatment to help alleviate constipation in people with MS.

Conclusion

This paper describes a feasibility study of the effectiveness of abdominal massage in relieving constipation in people with MS. Questionnaire response rates and compliance with treatment were high, and data analysis results indicated a potential positive effect of the intervention on the symptoms of constipation. Further research is now warranted in the form of a multi-centre randomized controlled clinical trial with an adequately powered sample size.

Acknowledgements

We would like to thank Marian Emly for her help with the massage technique.

Funding

This study was funded by a research grant from the Multiple Sclerosis Trust.

Conflict of interest

The author declares no conflicts of interest.

References

1. Nortvedt MW, Riise T, Frugard J, Mohn J, Bakke A, Skar AB, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. *Mult Scler* 2007; 13: 106–112.
2. Coggrave M, Wiesel PH and Norton C. Management of faecal incontinence and constipation in adults with central neurological diseases. *Cochrane Database Syst Rev* 2006; CD002115.

3. Hinds JP, Eidelman BH and Wald A. Prevalence of bowel dysfunction in multiple sclerosis. *Gastroenterology* 1990; 98: 1538–1542.
4. Glia A and Lindberg G. Quality of life in patients with different types of functional constipation. *Scand J Gastroenterol* 1997; 32: 1083–1089.
5. Friedrichsen M and Erichsen E. The lived experience of constipation in cancer patients in palliative hospital-based home care. *Int J Palliat Nurs* 2004; 10: 321–325.
6. Wiesel PH, Norton C, Roy A, Storrie J, Bowers J and Kamm M. Gut-focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2000; 69: 240–243.
7. Hinds JP and Wald A. Colonic and anorectal dysfunction associated with multiple sclerosis. *Am J Gastroenterol* 1989; 84: 587–595.
8. Fowler C. The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis. *Baillieres Clin Neurol* 1997; 6: 447–466.
9. Lembo A and Camillerai M. Current concepts: chronic constipation. *N Engl J Med* 2003; 349: 1360–1368.
10. Chia YW, Fowler C, Kamm M, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. *J Neurol* 1995; 242: 105–108.
11. Weber J, Delanger T, Hannequin D, et al. Anorectal manometric anomalies in seven patients with frontal lobe brain damage. *Dig Dis Sci* 1990; 35: 225–230.
12. Glick E, Meshkinpur H, Haldeman S, et al. Colonic dysfunction in multiple sclerosis. *Gastroenterology* 1982; 83: 1002–1007.
13. Waldron DJ, Horgan PG, Patel FR, et al. Multiple sclerosis: assessment of colonic and anorectal function in the presence of faecal incontinence. *Int J Colorectal Dis* 1993; 8: 220–224.
14. Winge K, Rasmussen D and Werdelin L. Constipation in neurological diseases. *J Neurol Neurosurg Psychiatry* 2003; 74: 13–19.
15. Trevelyan J. A true complement? *Nurs Times* 1996; 92: 42–43.
16. Cole A and Stanley E. Complementary therapies as a means of developing the scope of professional nursing practice. *J Adv Nurs* 1998; 27: 1171–1176.
17. MS Society. Patient Information Leaflet ‘Bowel and Bladder Problems’, www.mssociety.org.uk, (Accessed May 2008).
18. MS Trust. Patient Information Leaflet ‘Bowel problems in MS’, www.mstrust.org.uk, (Accessed May 2008).
19. Ernst E. Abdominal massage therapy for chronic constipation: A systematic review of controlled trials. *Forsch Komplementarmed* 1999; 6: 149–151.
20. Preece J. Introducing abdominal massage in palliative care for the relief of constipation. *Complement Ther Nurs Midwifery* 2002; 8: 101–105.
21. Jeon SY and Jung HM. The effects of abdominal meridian massage on constipation among CVA patients. *Taehan Kanho Hakhoe Chi* 2005; 35: 135–142.
22. Lamas K, Lindholm L, Stenlund L, Stenlund H, Engstrom B and Jacobsson C. Effects of abdominal massage in management of constipation – A randomized controlled trial. *Int J Nurs Stud* 2009; 46: 759–767.

23. Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum* 1996; 39: 681–685.
24. Krogh K, Christensen P, Sabore S and Laurberg A. Neurogenic Bowel Dysfunction Score. *Spinal Cord* 2006; 44: 625–631.
25. Hobart J, Lamping DL, Fitzpatrick R, Riazi A and Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. *Brain* 2001; 124: 962–973.
26. Bonniaud V, Jackowski D, Parratte B, Paulseth R, Grad S, Margetts P, et al. Quality of life in multiple sclerosis patients with urinary disorders; discriminative validation of the English version of Qualiveen. *Qual Life Res* 2005; 14: 425–431.
27. Bonniaud V, Bryant D, Parratte B and Guyatt G. Qualiveen, a urinary disorder specific instrument: 0.5 corresponds to the minimal important difference. *J Clin Epidemiol* 2008; 61: 505–510.
28. Liu Z, Sakakibara R, Odaka T, Uchiyama T, Yamamoto T, Ito T, et al. Mechanism of abdominal massage for difficult defecation in a patient with myelopathy (HAM/TSP). *J Neurol* 2005; 252: 1280–1282.
29. Allan D. The central nervous system. In: Montague SE, Watson R, Herbert RA (eds) *Physiology for Nursing Practice*. Philadelphia: Elsevier, 2005.
30. Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO, et al. *Neuroscience*. Massachusetts: Sinauer Associates, Inc., 2007.
31. Diego MA, Field T, Hernandez-Reif M, Deeds O, Ascencio A and Begert G. Preterm infant massage elicits consistent increases in vagal activity and gastric motility that are associated with greater weight gain. *Acta Paediatrica* 2007; 96: 1588–1591.
32. Longworth J. Psychophysiological effects of slow stroke back massage in normotensive females. *Adv Nurs Sci* 1982; 4: 44–60.
33. Ferrell-Torry AT and Glick OJ. The use of therapeutic massage as a nursing intervention to modify anxiety and the perception of cancer pain. *Cancer Nurs* 1993; 16: 93–101.
34. Stevenson CJ. The psychophysiological effects of aromatherapy massage following cardiac surgery. *Complement Ther Med* 1994; 2: 27–35.
35. Potter J, Norton C and Cottenden A. *Bowel Care in Older People*. London: Royal College of Physicians, 2002.
36. Medical Research Council. *A Framework for the Development and Evaluation of RCTs for Complex Interventions to Improve Health*. London: MRC, 2000.